The World Health Organization has declared a public health emergency of international concern following a surge of Ebola Bundibugyo virus cases across the Democratic Republic of the Congo (DRC) and Uganda. As of May 17, 2026, data from the U.S. Centers for Disease Control and Prevention indicates that the outbreak has been linked to 336 suspected cases and 88 deaths.
Unlike the more common Zaire species of Ebola, Notice currently no approved vaccines or therapeutic treatments specifically for the Bundibugyo virus. This gap in the medical arsenal has triggered an urgent international effort to deploy experimental drugs and evaluate whether existing vaccines offer any cross-protection against this rarer strain.
Clinical researchers are now working to launch trials for two primary investigational therapies. These efforts are being coordinated under a WHO-sponsored framework, pending final regulatory approvals from the governments of Uganda and the DRC. The goal is to move from laboratory data to bedside application as quickly as possible to reduce the current fatality rate.
The Search for Effective Ebola Bundibugyo Virus Treatments
The current clinical strategy focuses on two distinct pharmacological approaches: a broad-spectrum antiviral and a targeted antibody cocktail. Because the Bundibugyo virus is a filovirus—the same family that includes the Marburg and Zaire viruses—scientists are leveraging research from previous outbreaks to find a viable solution.
One of the primary candidates is remdesivir, a broad-acting antiviral manufactured by Gilead Sciences. While remdesivir gained global prominence during the SARS-CoV-2 pandemic, its application in Ebola treatment dates back to a 2018–19 outbreak of the Zaire species in the DRC. In that instance, its efficacy was described as modest, but its ability to inhibit viral replication makes it a logical starting point for the Bundibugyo strain.
The second candidate, MBP134, represents a more targeted approach. Developed by Mapp Biopharmaceuticals, MBP134 is a mixture of two antibodies designed to recognize and neutralize diverse Ebola viruses. This therapy has already seen limited use. it was administered under “compassionate use” protocols during a 2022 Sudan species outbreak in Uganda. While those cases were not part of a controlled clinical trial—making it impossible to definitively prove efficacy—preclinical data remains promising.
Virologist Thomas Geisbert of the University of Texas Medical Branch notes that animal studies have shown MBP134 to be highly effective against the Bundibugyo virus. In a 2019 study, the treatment led to profound recovery in five out of six infected monkeys, even when administered after the onset of severe symptoms like fever. This suggests the drug may function as a true therapeutic that can save patients who are already critically ill.
| Therapy | Type | Developer | Previous Application |
|---|---|---|---|
| Remdesivir | Broad-acting Antiviral | Gilead Sciences | SARS-CoV-2; Zaire Ebola |
| MBP134 | Antibody Cocktail | Mapp Biopharmaceuticals | Sudan Ebola (Compassionate Use) |
The Vaccine Gap and the ‘Coin Flip’ of Cross-Protection
While treatment trials are moving forward, the path to a vaccine is more complex. The only approved Ebola vaccine, Ervebo, was developed to target the Zaire species and proved highly effective during the 2014–16 West Africa epidemic. However, the Bundibugyo virus is genetically distinct, leaving health officials to wonder if Ervebo provides any meaningful protection.
The Africa Centres for Disease Control and Prevention is currently evaluating the feasibility of trialing Ervebo in the current outbreak. The scientific community is divided on the likely outcome. Some early research from 2011 suggested that a Zaire-based vaccine could protect a majority of primate subjects from Bundibugyo infection, but those results are tricky to interpret because the virus was not completely lethal in the animal models used.
According to Dr. Geisbert, the effectiveness of Ervebo against the Bundibugyo strain is essentially a “coin flip,” with an estimated 50% efficacy rate. While not a perfect solution, a partially effective vaccine could still significantly slow the transmission of the virus in high-risk zones.
Logistical Hurdles and Next Steps
The speed of the response depends heavily on international cooperation, and logistics. Larry Zeitlan, CEO of Mapp Biopharmaceuticals, has confirmed that sufficient doses of MBP134 are available for a trial, with the drug stocks owned by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Government.
However, the transition from stockpiles to patients requires rigorous ethical oversight and government permission. Amanda Rojek, a clinical researcher at the University of Oxford, emphasizes that the team is working “day and night” to prepare the trials, but acknowledges that the early stages of an outbreak are volatile. The ability to enroll enough participants to reach statistical significance depends entirely on the trajectory of the virus’s spread.
For those monitoring the situation, official updates on case counts and trial approvals are being managed through the World Health Organization and the respective health ministries of the DRC and Uganda.
Disclaimer: This article is provided for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next critical checkpoint will be the formal announcement of trial approvals from the DRC and Ugandan governments, which will determine when the first doses of remdesivir and MBP134 can be administered to patients in the field.
We invite readers to share this report and leave their thoughts in the comments section below.
